Interpretation of an extended autoantibody profile in a well-characterized Australian systemic sclerosis (Scleroderma) cohort using principal components analysis

Arthritis and Rheumatology

Volumn 67, Issue 12, 2015, Pages 3234-3244

  Patterson, K A ^a,m   Roberts Thomson, P J ^a,b   Lester, S ^c   Tan, J A ^d   Hakendorf, P ^d   Rischmueller, M ^c,e   Zochling, J ^f   Sahhar, J ^g   Nash, P ^h   Roddy, J ⁱ   Hill, C ^e   Nikpour, M ^j   Stevens, W ^k   Proudman, S M ^e   Walker, J G ^a,l  

^a FLINDERS UNIVERSITY   (Australia)

^b SA PATHOLOGY   (Australia)

^c QUEEN ELIZABETH HOSPITAL   (Australia)

^d FLINDERS MEDICAL CENTRE   (Australia)

^e UNIVERSITY OF ADELAIDE   (Australia)

^f UNIVERSITY OF TASMANIA   (Australia)

^g SOUTHERN HEALTH   (Australia)

^h UNIVERSITY OF QUEENSLAND   (Australia)

ⁱ ROYAL PERTH HOSPITAL   (Australia)

^j UNIVERSITY OF MELBOURNE   (Australia)

^k ST VINCENT S HOSPITAL   (Australia)

^l REPATRIATION GENERAL HOSPITAL   (Australia)

^m CSIRO   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CENTROMERE PROTEIN A; CENTROMERE PROTEIN B; DNA DIRECTED RNA POLYMERASE III; DNA TOPOISOMERASE; EPITOPE; FIBRILLARIN; AUTOANTIGEN; CELL NUCLEUS ANTIGEN; CENPB PROTEIN, HUMAN; DNA BINDING PROTEIN; EXORIBONUCLEASE; EXOSC10 PROTEIN, HUMAN; EXOSC9 PROTEIN, HUMAN; EXOSOME MULTIENZYME RIBONUCLEASE COMPLEX; KU ANTIGEN; NONHISTONE PROTEIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RIBONUCLEOPROTEIN; RNA BINDING PROTEIN; SS-A ANTIGEN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR UBF;

ADULT; ARTICLE; AUSTRALIAN; CENTROMERE; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; IMMUNOASSAY; IMMUNOBLOTTING; JOINT CONTRACTURE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; SEROLOGY; STOMACH ANTRUM VASCULAR ECTASIA; SYSTEMIC SCLEROSIS; TELANGIECTASIA; AGED; AUSTRALIA; COMPLICATION; CONTRACTURE; ESOPHAGEAL MOTILITY DISORDERS; GASTRIC ANTRAL VASCULAR ECTASIA; IMMUNOLOGY; NEOPLASMS; PRINCIPAL COMPONENT ANALYSIS; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; SEX DIFFERENCE; SMOKING; TELANGIECTASIS;

AGED; ANTIGENS, NUCLEAR; AUSTRALIA; AUTOANTIBODIES; AUTOANTIGENS; CENTROMERE PROTEIN B; CHROMOSOMAL PROTEINS, NON-HISTONE; COHORT STUDIES; CONTRACTURE; DNA TOPOISOMERASES, TYPE I; DNA-BINDING PROTEINS; ESOPHAGEAL MOTILITY DISORDERS; EXORIBONUCLEASES; EXOSOME MULTIENZYME RIBONUCLEASE COMPLEX; FEMALE; GASTRIC ANTRAL VASCULAR ECTASIA; HUMANS; IMMUNOBLOTTING; MALE; MIDDLE AGED; NEOPLASMS; POL1 TRANSCRIPTION INITIATION COMPLEX PROTEINS; PRINCIPAL COMPONENT ANALYSIS; RAYNAUD DISEASE; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RIBONUCLEOPROTEINS; RNA POLYMERASE III; RNA-BINDING PROTEINS; SCLERODERMA, SYSTEMIC; SEX FACTORS; SMOKING; TELANGIECTASIS;

EID: 84948440607     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39316     Document Type: Article

References (55)

1. Martin JE, Bossini-Castillo L, Martin J., Unraveling the genetic component of systemic sclerosis. Hum Genet 2012; 131: 1023-37.
2. Dieude P, Boileau C, Allanore Y., Immunogenetics of systemic sclerosis. Autoimmun Rev 2011; 10: 282-90.
3. Haustein UF., Systemic sclerosis-scleroderma. Dermatol Online J 2002; 8: 3.
4. Roberts-Thomson PJ, Walker JG., Stochastic processes in the aetiopathogenesis of scleroderma. Intern Med J 2012; 42: 235-42.
5. Mayes MD., Scleroderma epidemiology. Rheum Dis Clin North Am 2003; 29: 239-54.
6. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
7. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al., Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 1988; 15: 202-5.
8. Maricq HR, Valter I., A working classification of scleroderma spectrum disorders: a proposal and the results of testing on a sample of patients. Clin Exp Rheumatol 2004; 22 Suppl 33: S5-13.
9. Varga J, Hinchcliff M., Connective tissue diseases: systemic sclerosis: beyond limited and diffuse subsets? Nat Rev Rheumatol 2014; 10: 200-2.
10. Van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al., 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2013; 65: 2737-47.
11. Walker JG, Fritzler MJ., Update on autoantibodies in systemic sclerosis. Curr Opin Rheumatol 2007; 19: 580-91.
12. Mehra S, Walker J, Patterson K, Fritzler MJ., Autoantibodies in systemic sclerosis. Autoimmun Rev 2013; 12: 340-54.
13. Hudson M, Pope J, Mahler M, Tatibouet S, Steele R, Baron M, et al., Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis. Arthritis Res Ther 2012; 14: R50.
14. Graf SW, Hakendorf P, Lester S, Patterson K, Walker JG, Smith MD, et al., South Australian Scleroderma Register: autoantibodies as predictive biomarkers of phenotype and outcome. Int J Rheum Dis 2012; 15: 102-9.
15. National Health and Medical Research Council, Australian Research Council, and Australian Vice-Chancellor's Committee. National statement on ethical conduct in human research 2007 (updated May 2015). URL: http://www.nhmrc.gov.au/guidelines-publications/e72.
16. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. Bull World Health Organ 2001; 79: 373-4.
17. LeRoy EC, Medsger TA Jr., Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28: 1573-6.
18. Hudson M, Fritzler MJ, Baron M., Systemic sclerosis: establishing diagnostic criteria. Medicine (Baltimore) 2010; 89: 159-65.
19. Nikpour M, Hissaria P, Byron J, Sahhar J, Micallef M, Paspaliaris W, et al., Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort. Arthritis Res Ther 2011; 13: R211.
20. Low AH, Wong S, Thumboo J, Ng SC, Lim JY, Ng X, et al., Evaluation of a new multi-parallel line immunoassay for systemic sclerosis-associated antibodies in an Asian population. Rheumatology (Oxford) 2012; 51: 1465-70.
21. Mierau R, Moinzadeh P, Riemekasten G, Melchers I, Meurer M, Reichenberger F, et al., Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features. Arthritis Res Ther 2011; 13: R172.
22. Villalta D, Imbastaro T, Di Giovanni S, Lauriti C, Gabini M, Turi MC, et al., Diagnostic accuracy and predictive value of extended autoantibody profile in systemic sclerosis. Autoimmun Rev 2012; 12: 114-20.
23. Husson F, Josse J, Le S, Mazet J., Multivariate exploratory data analysis and data mining with R: an R package for exploratory data analysis. FactoMineR package version 1.25. 2013. URL: http://factominer.free.fr.
24. Steen VD., Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005; 35: 35-42.
25. Mehra S, Hudson M, Mahler M, Canadian Scleroderma Research Group, Baron M, Fritzler M., Is there an association between Ro52/TRIM21 antibodies and rheumatoid factor in systemic sclerosis? Rheumatol Int 2014; 34: 425-7.
26. Hanitsch LG, Burmester GR, Witt C, Hunzelmann N, Genth E, Krieg T, et al., Skin sclerosis is only of limited value to identify SSc patients with severe manifestations-an analysis of a distinct patient subgroup of the German Systemic Sclerosis Network (DNSS) Register. Rheumatology (Oxford) 2009; 48: 70-3.
27. Miller CS., Skin-deep diagnosis: affective bias and zebra retreat complicating the diagnosis of systemic sclerosis. Am J Med Sci 2013; 345: 53-6.
28. Krzyszczak ME, Li Y, Ross SJ, Ceribelli A, Chan EK, Bubb MR, et al., Gender and ethnicity differences in the prevalence of scleroderma-related autoantibodies. Clin Rheumatol 2011; 30: 1333-9.
29. Hudson M, Mahler M, Pope J, You D, Tatibouet S, Steele R, et al., Clinical correlates of CENP-A and CENP-B antibodies in a large cohort of patients with systemic sclerosis. J Rheumatol 2012; 39: 787-94.
30. Steen V, Domsic RT, Lucas M, Fertig N, Medsger TA Jr., A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis. Arthritis Rheum 2012; 64: 2986-94.
31. Nihtyanova SI, Parker JC, Black CM, Bunn CC, Denton CP., A longitudinal study of anti-RNA polymerase III antibody levels in systemic sclerosis. Rheumatology (Oxford) 2009; 48: 1218-21.
32. Mouthon L, Bussone G, Berezne A, Noel LH, Guillevin L., Scleroderma renal crisis. J Rheumatol 2014; 41: 1040-8.
33. Hung EW, Mayes MD, Sharif R, Assassi S, Machicao VI, Hosing C, et al., Gastric antral vascular ectasia and its clinical correlates in patients with early diffuse systemic sclerosis in the SCOT trial. J Rheumatol 2013; 40: 455-60.
34. Ingraham KM, O'Brien MS, Shenin M, Derk CT, Steen VD., Gastric antral vascular ectasia in systemic sclerosis: demographics and disease predictors. J Rheumatol 2010; 37: 603-7.
35. Lepri G, Guiducci S, Bellando-Randone S, Giani I, Bruni C, Blagojevic J, et al., Evidence for oesophageal and anorectal involvement in very early systemic sclerosis (VEDOSS): report from a single VEDOSS/EUSTAR centre. Ann Rheum Dis 2015; 74: 124-8.
36. Thonhofer R, Siegel C, Trummer M, Graninger W., Early endoscopy in systemic sclerosis without gastrointestinal symptoms. Rheumatol Int 2012; 32: 165-8.
37. Meyer OC, Fertig N, Lucas M, Somogyi N, Medsger TA Jr., Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol 2007; 34: 104-9.
38. Vanthuyne M, Smith V, De Langhe E, Van Praet J, Arat S, Depresseux G, et al., The Belgian Systemic Sclerosis Cohort: correlations between disease severity scores, cutaneous subsets, and autoantibody profile. J Rheumatol 2012; 39: 2127-33.
39. Sobanski V, Dauchet L, Lefevre G, Lambert M, Morell-Dubois S, Sy T, et al., Prevalence of anti-RNA polymerase III antibodies in systemic sclerosis: new data from a French cohort and a systematic review and meta-analysis. Arthritis Rheumatol 2014; 66: 407-17.
40. Hamaguchi Y, Hasegawa M, Fujimoto M, Matsushita T, Komura K, Kaji K, et al., The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis. Br J Dermatol 2008; 158: 487-95.
41. Wang J, Assassi S, Guo G, Tu W, Wu W, Yang L, et al., Clinical and serological features of systemic sclerosis in a Chinese cohort. Clin Rheumatol 2013; 32: 617-21.
42. Rodriguez-Reyna TS, Hinojosa-Azaola A, Martinez-Reyes C, Nunez-Alvarez CA, Torrico-Lavayen R, Garcia-Hernandez JL, et al., Distinctive autoantibody profile in Mexican Mestizo systemic sclerosis patients. Autoimmunity 2011; 44: 576-84.
43. Domsic RT., Scleroderma: the role of serum autoantibodies in defining specific clinical phenotypes and organ system involvement. Curr Opin Rheumatol 2014; 26: 646-652.
44. Moinzadeh P, Fonseca C, Hellmich M, Shah AA, Chighizola C, Denton CP, et al., Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma. Arthritis Res Ther 2014; 16: R53.
45. Shah AA, Rosen A, Hummers L, Wigley F, Casciola-Rosen L., Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis Rheum 2010; 62: 2787-95.
46. Australian Institute of Health and Welfare and Cancer Australia. Non-melanoma skin cancer: general practice consultations, hospitalisation and mortality. Canberra: Australian Institute of Health and Welfare; September 2008. URL: http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=6442454591.
47. Le Guern V, Mahr A, Mouthon L, Jeanneret D, Carzon M, Guillevin L., Prevalence of systemic sclerosis in a French multi-ethnic county. Rheumatology (Oxford) 2004; 43: 1129-37.
48. Hashimoto A, Endo H, Kondo H, Hirohata S., Clinical features of 405 Japanese patients with systemic sclerosis. Mod Rheumatol 2012; 22: 272-9.
49. Sujau I, Ng CT, Sthaneshwar P, Sockalingam S, Cheah TE, Yahya F, et al., Clinical and autoantibody profile in systemic sclerosis: baseline characteristics from a West Malaysian cohort. Int J Rheum Dis 2015; 18: 459-65.
50. Sanchez-Montalva A, Fernandez-Luque A, Simeon CP, Fonollosa-Pla V, Marin A, Guillen A, et al., Anti-SSA/Ro52 autoantibodies in scleroderma: results of an observational, cross-sectional study. Clin Exp Rheumatol 2014; 32 Suppl 86: S-177-82.
51. D'Aoust J, Hudson M, Tatibouet S, Wick J, the Canadian Scleroderma Research Group, Mahler M, et al., Clinical and serologic correlates of anti-PM/Scl antibodies in systemic sclerosis: a multicenter study of 763 patients. Arthritis Rheumatol 2014; 66: 1608-15.
52. Koschik RW II, Fertig N, Lucas MR, Domsic RT, Medsger TA Jr., Anti-PM-Scl antibody in patients with systemic sclerosis. Clin Exp Rheumatol 2012; 30 Suppl 71: S12-6.
53. Ghillani P, Andre C, Toly C, Rouquette AM, Bengoufa D, Nicaise P, et al., Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60kDa antibodies: results of a multicentric study. Autoimmun Rev 2011; 10: 509-13.
54. Virendrakumar Bhavsar S, Carmona R., Anti-RNA polymerase III antibodies in the diagnosis of scleroderma renal crisis in the absence of skin disease. J Clin Rheumatol 2014; 20: 379-82.
55. Cottrell TR, Wise RA, Wigley FM, Boin F., The degree of skin involvement identifies distinct lung disease outcomes and survival in systemic sclerosis. Ann Rheum Dis 2014; 73: 1060-6.